viral
infect
major
global
health
problem
repres
signific
caus
mortal
unfavor
continu
amplifi
socioeconom
impact
increas
drug
resist
constant
viral
replic
trigger
import
studi
regard
use
nanotechnolog
antivir
therapi
nanomateri
offer
uniqu
physicochem
properti
link
benefit
drug
deliveri
ideal
tool
viral
treatment
current
differ
type
nanomateri
name
nanoparticl
liposom
nanospher
nanogel
nanosuspens
nanoemuls
studi
either
vitro
vivo
drug
deliveri
antivir
agent
prospect
translat
clinic
practic
review
highlight
drug
deliveri
nanosystem
incorpor
major
antivir
class
transport
across
specif
barrier
cellular
intracellular
level
import
reflect
nanomedicin
current
approv
undergo
investig
treatment
viral
infect
also
discuss
final
author
present
overview
requir
design
antivir
nanotherapeut
today
live
socal
fourth
great
transit
period
three
wave
epidemiolog
transit
name
earli
agrarianbas
settlement
earli
eurasian
civil
european
expansion
detail
found
mcmichael
descript
current
configur
varieti
infecti
diseas
close
follow
combin
evolut
demographi
environ
technolog
social
chang
behaviour
medicin
creat
new
opportun
microb
either
blood
transfus
organ
transplant
use
hypoderm
syring
excess
use
antibiot
thu
contribut
induct
iatrogen
effect
treatment
infect
hepat
c
hiv
other
recent
decad
old
concern
reactiv
offici
gener
public
level
regard
infecti
diseas
threat
public
health
mcmichael
analyz
reflect
issu
social
media
notic
emerg
resurg
infecti
diseas
determin
environment
sociolog
econom
chang
socal
public
anxieti
set
topic
despit
widespread
increas
transmiss
still
poor
understand
global
econom
impact
viral
diseas
make
difficult
evalu
societ
cost
costeffect
prevent
effort
issu
estim
gener
impact
viral
infect
involv
sever
aspect
hinder
approach
name
varieti
viral
infect
incid
associ
comorbid
social
psycholog
issu
econom
repercuss
hidden
cost
varieti
treatment
directact
antivir
daa
vaccin
use
evalu
presenc
neg
extern
mean
diseas
consequ
limit
patient
infect
potenti
also
relat
famili
may
experi
social
distress
well
also
human
mobil
longdist
trade
increas
everlarg
citi
often
gird
slum
becom
highway
microbi
traffic
poverti
perpetu
vulner
infecti
diseas
sexual
practic
drug
inject
intensifi
food
product
much
modern
medic
technolog
creat
new
audienc
microbi
opportun
new
manag
issu
public
health
decis
maker
reason
global
assess
socioeconom
impact
seem
practic
imposs
contrari
could
meet
criteria
relev
rather
impact
split
relev
categori
viral
infect
literatur
precis
even
remain
inconsist
regard
unif
methodolog
variou
studi
ensur
compar
data
figur
present
statist
fact
relat
burdengener
viral
infect
diseas
pharmaceut
x
peer
review
recent
decad
old
concern
reactiv
offici
gener
public
level
regard
infecti
diseas
threat
public
health
mcmichael
analyz
reflect
issu
social
media
notic
emerg
resurg
infecti
diseas
determin
environment
sociolog
econom
chang
socal
public
anxieti
set
topic
despit
widespread
increas
transmiss
still
poor
understand
global
econom
impact
viral
diseas
make
difficult
evalu
societ
cost
costeffect
prevent
effort
issu
estim
gener
impact
viral
infect
involv
sever
aspect
hinder
approach
name
varieti
viral
infect
incid
associ
comorbid
social
psycholog
issu
econom
repercuss
hidden
cost
varieti
treatment
directact
antivir
daa
vaccin
use
evalu
presenc
neg
extern
mean
diseas
consequ
limit
patient
infect
potenti
also
relat
famili
may
experi
social
distress
well
also
human
mobil
longdist
trade
increas
everlarg
citi
often
gird
slum
becom
highway
microbi
traffic
poverti
perpetu
vulner
infecti
diseas
sexual
practic
drug
inject
intensifi
food
product
much
modern
medic
technolog
creat
new
audienc
microbi
opportun
new
manag
issu
public
health
decis
maker
reason
global
assess
socioeconom
impact
seem
practic
imposs
contrari
could
meet
criteria
relev
rather
impact
split
relev
categori
viral
infect
literatur
precis
even
remain
inconsist
regard
unif
methodolog
variou
studi
ensur
compar
data
figur
present
statist
fact
relat
burdengener
viral
infect
diseas
hivaid
consid
one
major
burden
diseas
global
becam
chronic
diseas
introduct
multipl
antiretrovir
therapi
art
therefor
need
provid
long
hivaid
consid
one
major
burden
diseas
global
becam
chronic
diseas
introduct
multipl
antiretrovir
therapi
art
therefor
need
provid
longterm
care
support
ill
person
demand
higher
level
treatment
cost
hivaffect
household
consequ
hivaid
caus
deplet
save
product
asset
increas
indebted
hivaffect
household
moreov
higher
health
care
expenditur
household
reduc
invest
nutrit
food
famili
member
invest
farm
busi
children
educ
death
work
age
patient
major
factor
econom
impact
hivaid
household
level
impact
hivaid
includ
direct
cost
includ
medic
nonmed
cost
product
cost
loss
labour
time
result
morbid
hiv
posit
household
member
well
time
spent
other
care
evid
suggest
hivaid
place
signific
econom
pressur
household
tri
pay
health
care
cost
tri
make
lost
incom
difficulti
accur
quantifi
explain
morbid
mortal
relat
viral
hepat
stem
fact
hepat
death
caus
five
distinct
virus
hepat
ae
differ
rout
transmiss
fact
death
occur
decad
infect
peopl
die
hepatitisrel
liver
cancer
cirrhosi
death
alway
link
underli
infect
although
antivir
therapi
appear
expens
exampl
averag
cost
treat
hcv
case
rang
consid
also
cost
effect
compar
wellaccept
medic
intervent
due
sustain
viral
respons
therapi
cost
save
qualityoflif
improv
prolong
life
expect
prevent
hcv
complic
era
new
daa
statement
provid
treatment
hcvpatient
gener
save
compar
provid
low
middleincom
countri
may
consid
hcvtreatment
costsav
intervent
health
system
longterm
horizon
year
econom
impact
treatment
higher
treatment
cost
still
enthusiasm
daa
therapi
howev
temper
two
major
concern
price
still
high
medic
challeng
patient
clinician
face
respect
drug
access
mani
countri
hsv
herp
zoster
varicellazosterian
virusvzv
reactiv
common
infect
human
effect
treatment
avail
time
impact
health
degre
vari
small
impair
sever
disabl
form
case
limit
method
appli
local
infect
reduc
side
effect
pain
manifest
dermi
etc
also
specif
psycholog
issu
relat
diseas
neg
feel
correl
condit
follow
diagnosi
particular
acquir
genit
form
diseas
feel
includ
depress
fear
reject
feel
isol
fear
found
selfdestruct
feel
mention
avail
report
present
crude
estim
rather
precis
measur
econom
cost
ill
cost
calcul
directli
intervent
medic
budgetari
chapter
without
take
account
societ
loss
moreov
differ
approach
discrep
explain
least
part
influenc
complianc
treatment
possibl
sampl
subpopul
data
set
also
limit
must
place
abil
gener
result
beyond
sampl
moreov
cost
matter
cost
intervent
compar
result
intervent
effect
treatment
effici
produc
societ
gain
must
offset
loss
usual
accur
methodolog
estim
burden
associ
diseas
socal
costofil
measur
cost
particular
diseas
includ
direct
indirect
intang
dimens
wide
accept
estim
total
social
cost
diseas
use
establish
polici
decis
also
method
crosssect
survey
sampl
primari
secondari
care
physician
analyz
health
care
resourc
util
approach
base
analysi
larg
administr
data
set
valu
spend
drug
consum
list
approach
use
estim
number
patient
seek
medic
treatment
averag
medic
expenditur
health
input
employ
per
unit
multipli
number
unit
estim
nation
cost
comprehens
studi
often
advantag
alloc
total
nation
expenditur
among
major
diagnost
categori
howev
regardless
method
analyz
possibl
otherwis
insid
countri
impact
determin
cultur
social
aspect
vari
substanti
even
absenc
global
data
natur
still
extract
inform
present
relev
issu
topic
paper
current
arrang
manag
viral
infect
treatment
prevent
limit
spread
costli
less
effect
unafford
case
burdensom
medic
system
exampl
accord
current
analysi
globe
newswir
report
data
global
antivir
drug
market
valu
billion
expect
reach
billion
year
sale
antivir
increas
approxim
two
year
moreov
thank
better
diagnost
innov
drug
new
therapeut
market
like
wit
even
futur
growth
howev
list
viral
diseas
antivir
therapi
avail
still
rel
short
sever
factor
hinder
develop
antivir
drug
depend
virus
replic
host
cell
biosynthet
machineri
lead
limit
number
virusspecif
metabol
function
target
antivir
drug
without
damag
host
virus
function
specif
viru
prevent
develop
broadspectrum
antivir
fight
differ
virus
caus
similar
symptom
antivir
develop
virus
hsv
hiv
treat
acut
ill
cure
latent
infect
lead
recurr
chronic
diseas
requir
treatment
longer
period
time
limit
prompt
need
paradigm
shift
great
challeng
antivir
therapi
move
develop
new
drug
formula
involv
chang
physicochem
biopharmaceut
properti
antivir
molecul
use
new
scientif
strategi
prepar
dosag
configur
virus
submicroscop
intracellular
parasit
particl
genet
materi
contain
protein
coat
total
depend
host
cell
replic
show
live
nonliv
characterist
live
characterist
virus
repres
high
rate
multipl
live
host
cell
abil
mutat
nonliv
characterist
virus
consist
acellular
lack
cytoplasm
organel
replic
use
host
cell
metabol
machineri
composit
dna
rna
human
viral
infect
respons
differ
diseas
briefli
present
tabl
accord
intern
committe
taxonomi
virus
ictv
phylum
subphylia
six
class
order
seven
subord
famili
subfamili
genera
subgenera
speci
current
virus
classifi
base
type
nucleic
acid
dna
rna
singlestrand
doublestrand
way
replic
known
baltimor
classif
divid
seven
baltimor
class
idsdna
virus
eg
adenovirus
herpesvirus
poxvirus
enter
host
nucleu
depend
host
cell
polymeras
replic
viral
genom
viru
may
induc
cell
forc
undergo
cell
divis
may
lead
transform
cell
ultim
cancer
iissdna
virus
strand
sens
dna
eg
parvovirus
consist
virus
singlestrand
dna
genom
polar
mrna
except
parvovirus
circular
genom
replic
within
nucleu
iiidsrna
virus
eg
reovirus
depend
host
replic
polymeras
replic
monocistron
realiz
capsid
cytoplasm
iv
ssrna
virus
strand
sens
rna
eg
picornavirus
togavirus
rna
directli
access
ribosom
host
form
protein
use
simpl
reproduct
pathway
virus
polycistron
mrna
complex
transcript
pathway
subgenom
mrna
ribosom
frameshift
proteolyt
process
polyprotein
may
use
gastroenter
adenovirus
rotavirus
norovirus
astrovirus
coronavirus
sexual
transmit
diseas
herp
simplex
type
human
papillomaviru
hiv
distinct
stage
viral
replic
cell
entri
uncoat
transcript
viral
genom
translat
viral
protein
posttransl
modif
assembl
virion
compon
class
antivir
agent
act
stage
correspond
stage
replic
class
select
inhibitor
describ
detail
refer
pharmacolog
properti
follow
next
section
accord
knowledg
base
found
studi
antivir
summar
figur
appli
nanomedicin
therapi
larg
hsv
famili
doublestrand
dna
virus
wide
distribut
among
human
includ
highli
select
effect
antivir
acyclovir
acv
ganciclovir
gcv
incorpor
nanomateri
complet
classif
hsv
antivir
pharmaceut
found
describ
detail
refer
briefli
acv
pharmacolog
explain
follow
acv
select
depend
interact
viral
hsv
thymidin
kinas
dna
polymeras
therefor
cellular
uptak
first
phosphoril
facilit
hsv
thymidin
kinas
present
high
affin
acv
intracellular
enzym
convert
monophosp
triphosph
acv
form
acv
inhibit
viral
dna
polymeras
much
lesser
extent
cellular
dna
polymeras
acv
triphosph
also
integr
viral
dna
act
chain
termin
bind
viral
dna
polymeras
determin
irrevers
inactiv
mechan
call
suicid
inactiv
occurr
resist
acv
could
acquir
three
mechan
impair
product
viral
thymidin
kinas
common
alter
thymidin
kinas
substrat
specif
eg
phosphoryl
thymidin
acyclovir
alter
viral
dna
polymeras
rare
alter
viral
enzym
caus
point
mutat
base
insert
delet
correspond
gene
accord
knowledg
base
found
studi
antivir
summar
figur
appli
nanomedicin
therapi
larg
hsv
famili
doublestrand
dna
virus
wide
distribut
among
human
includ
highli
select
effect
antivir
acyclovir
acv
ganciclovir
gcv
incorpor
nanomateri
complet
classif
hsv
antivir
found
describ
detail
refer
briefli
acv
pharmacolog
explain
follow
acv
select
depend
interact
viral
hsv
thymidin
kinas
dna
polymeras
therefor
cellular
uptak
first
phosphoril
facilit
hsv
thymidin
kinas
present
high
affin
acv
intracellular
enzym
convert
monophosp
triphosph
acv
form
acv
inhibit
viral
dna
polymeras
much
lesser
extent
cellular
dna
polymeras
acv
triphosph
also
integr
viral
dna
act
chain
termin
bind
viral
dna
polymeras
determin
irrevers
inactiv
mechan
call
suicid
inactiv
occurr
resist
acv
could
acquir
three
mechan
impair
product
viral
thymidin
kinas
common
alter
thymidin
kinas
substrat
specif
eg
phosphoryl
thymidin
acyclovir
alter
viral
dna
polymeras
rare
alter
viral
enzym
caus
point
mutat
base
insert
delet
correspond
gene
mechan
gcv
inhibit
viral
dna
synthesi
briefli
explain
monophosphoryl
intracellular
viral
thymidin
kinas
hsv
infect
viral
phosphotransferas
encod
gene
cmv
infect
diphosph
gcv
triphosph
form
produc
cellular
enzym
mechan
gcv
inhibit
viral
dna
synthesi
briefli
explain
monophosphoryl
intracellular
viral
thymidin
kinas
hsv
infect
viral
phosphotransferas
encod
gene
cmv
infect
diphosph
gcv
triphosph
form
produc
cellular
enzym
cmv
becom
resist
gcv
mutat
viral
phosphotransferas
encod
gene
mutat
viral
dna
polymeras
convent
treatment
prophylaxi
therapi
influenza
viru
infect
major
public
health
concern
worldwid
design
target
viral
protein
could
use
either
alon
combin
includ
also
amantadin
neuraminidas
inhibitor
zanamivir
oseltamivir
encapsul
nanoparticl
specifi
tabl
potent
vacuolar
atpas
vatpas
inhibitor
name
diphyllin
bafilomycin
previous
shown
broadspectrum
antivir
activ
repres
anoth
possibl
influenza
viru
infect
briefli
antivir
mechan
amantadin
base
nterfer
viral
protein
ion
channel
protein
need
viral
particl
becom
uncoat
taken
insid
cell
endocytosi
also
oseltamivir
carboxyl
mechan
impli
select
inhibit
influenza
viru
neuraminidas
enzym
glycoprotein
found
virion
surfac
import
viral
entri
uninfect
cell
releas
recent
form
viru
particl
infect
cell
spread
infecti
viru
bodi
hepat
virus
subject
intens
studi
last
year
special
attent
therapi
mention
first
section
hepat
treatment
depend
upon
type
hepat
therefor
differ
antivir
consid
summar
detail
refer
current
interferon
ifn
antivir
activ
first
two
produc
nearli
cell
respons
viral
infect
third
restrict
tlymphocyt
nk
cell
ifninduc
protein
includ
oligoadenyl
synthetas
protein
kinas
either
inhibit
protein
synthesi
presenc
doublestrand
rna
synthetas
produc
adenyl
oligom
activ
latent
cellular
endoribonucleas
rnase
l
cleav
cellular
viral
singlestrand
rna
antiretrovir
therapyartref
treatment
hiv
medicin
accord
last
updat
list
approv
food
drug
administr
fda
drug
classifi
seen
figur
follow
paragraph
author
describ
pharmacolog
mechan
medicin
hiv
treatment
includedencapsulatedincorpor
nanomateri
repres
nucleosid
revers
transcriptas
inhibitor
nrti
zidovudin
azt
phosphoryl
intracellular
kinas
specif
azt
triphosph
metabolit
respons
termin
elong
provir
dna
incorpor
revers
transcriptas
nascent
dna
lack
hydroxyl
group
resist
azt
associ
mutat
revers
transcriptas
codon
also
lamivudin
lam
anoth
nrti
agent
enter
cell
passiv
diffus
convert
monophosph
deoxycytidin
kinas
undergo
phosphoryl
deoxycytidin
monophosph
kinas
nucleosid
diphosph
kinas
yield
lamivudin
triphosph
activ
anabolit
tenofovir
disoproxil
deriv
adenosin
monophosph
lack
complet
ribos
ring
nucleotid
analogu
current
market
treatment
hiv
infect
activ
hbv
rapid
hydrolysi
tenofovir
form
phosphoryl
cellular
kinas
activ
metabolit
tenofovir
diphosph
competit
inhibitor
viral
revers
transcriptas
incorpor
hiv
dna
caus
chain
termin
nonnucleosid
revers
transcriptas
inhibitor
nnrti
includ
varieti
chemic
substrat
bind
hydrophob
pocket
subunit
revers
transcriptas
induc
conform
chang
structur
enzym
greatli
reduc
activ
thu
act
noncompetit
inhibitor
unlik
nucleosid
nucleotid
revers
transcriptas
inhibitor
compound
requir
intracellular
phosphoryl
attain
activ
also
bind
site
nnrti
virusstrainspecif
approv
agent
activ
retrovirus
use
treat
infect
hiv
proteas
inhibitor
pi
peptidelik
chemic
competit
inhibit
action
viru
aspartyl
proteas
homodim
consist
two
acid
monom
prefer
cleavag
site
enzym
ntermin
side
prolin
residu
especi
phenylalanin
prolin
drug
prevent
proteolyt
cleavag
hiv
gag
pol
precursor
polypeptid
includ
essenti
structur
enzymat
revers
transcriptas
proteas
integras
compon
viru
prevent
metamorphosi
hiv
viru
particl
matur
infecti
form
sqv
indinavir
atv
rtv
nfv
lopinavir
current
employ
nanotechnolog
research
two
drug
avail
entri
inhibitor
class
enfuvirtideenf
maravirocmcv
differ
mechan
action
incorpor
nanoparticl
specifi
tabl
enf
inhibit
fusion
viral
cell
membran
mediat
interact
mcv
chemokin
receptor
antagonist
bind
host
cell
receptor
block
bind
viral
mcv
approv
antiretrovir
drug
target
host
protein
raltegravir
ral
first
approv
hiv
integras
inhibitor
potent
activ
also
retain
activ
virus
becom
resist
antiretrovir
agent
class
uniqu
mechan
action
ral
encapsul
polymer
plga
nanoformul
gold
nanoparticl
see
tabl
first
line
defenc
substanc
encount
biolog
barrier
penetr
organ
secur
system
includ
physiolog
barrier
bloodbrain
barrier
bbb
epithelium
stratum
corneum
airblood
lung
barrier
reproduct
system
barrier
etc
control
extracellular
intracellular
access
traffick
foreign
substanc
bacteria
virus
fungi
chemic
also
provid
select
access
suitabl
candid
nutrit
andor
therapi
molecul
well
establish
one
mechan
may
involv
intracellular
drug
deliveri
mechan
involv
nanobas
intracellular
drug
deliveri
includ
passiv
diffus
free
drug
nonspecif
phagocytosi
nanocarri
nanocarri
uptak
pinocytosi
receptormedi
endocytosi
section
discuss
particular
overcom
biolog
barrier
mucu
skin
cell
membran
bbb
antivir
therapi
gastrointestin
tract
respiratori
system
urogenit
caviti
eye
mouth
cover
mucos
membran
highli
adhes
mucu
act
protect
layer
well
lubric
purpos
although
larg
molecul
pass
small
one
along
virus
easili
penetr
also
reason
drug
deliveri
challeng
mucu
contain
water
along
mucin
fibr
lipid
salt
cholesterol
protein
continu
produc
thick
ph
amount
differ
posit
two
strategi
follow
pass
mucu
mainli
depend
fast
turnov
fast
mucos
penetr
highli
adhes
particl
slow
turnov
increas
drug
resid
target
mucosa
mucoadhes
result
interact
like
hydrophob
hydrogen
bond
ionic
bond
van
der
waal
one
possibl
attract
interact
coval
bond
format
catechol
maleimid
thiol
acryl
domain
mucin
glycoprotein
rich
cystein
chitosan
algin
pectin
cellulos
polym
mostli
use
achiev
adhes
mucosa
furthermor
known
thiolat
mention
polym
develop
high
mucoadhes
properti
mucopenetr
second
strategi
found
permeat
mucu
layer
two
potenti
mechan
activ
strategi
character
interact
mucu
chemic
shift
featur
mucu
structur
passiv
strategi
use
hydrophil
enhanc
penetr
mucu
classic
hsv
therapi
includ
daili
dose
oral
administ
acv
effect
case
cours
problemat
case
exampl
longterm
use
acv
patient
report
resist
drug
follow
renal
injuri
anoth
issu
produc
standard
hsv
treatment
case
topic
form
trifluridin
tft
ganciclovir
acv
analog
gel
denot
low
retent
time
vagin
corneal
mucu
follow
multipl
dose
time
nanotechnolog
field
offer
great
deal
drug
deliveri
modal
order
overpass
biolog
barrier
deliv
effici
incorpor
activ
principl
control
target
pharmaceut
manner
reduc
circul
drug
level
attenu
renal
damag
recent
review
point
nanogel
base
abovement
materi
capabl
adequ
exampl
pass
type
biolog
barrier
exampl
synthes
nanodrug
deliveri
micel
base
chitosangoligo
nipaam
copolym
stabilis
ionotrop
crosslink
raskin
et
al
gave
good
result
deliv
antiretrovir
drug
efv
mucosa
studi
acv
penetr
differ
barrier
found
tabl
detail
section
import
mention
special
barrier
name
ocular
mucu
chang
complet
min
make
drug
absorpt
unfavour
addit
eye
protect
bloodanterior
chamber
bloodretin
barrier
case
drug
administr
combin
penetr
adhes
substanc
necessari
polym
like
phosphotyrosin
could
solut
demonstr
intestin
alkalin
phosphatas
present
polym
manifest
zeta
potenti
chang
thu
caus
immobil
penetr
anoth
kind
construct
combin
adhes
penetr
thiolat
system
mucolyt
enzym
ph
depend
therefor
acid
ph
absenc
disulphid
bond
format
cysteinerich
domain
mucin
manifest
mucos
adhes
unless
near
epithelium
skin
largest
organ
bodi
protect
us
microorgan
chemic
regul
bodi
temperatur
maintain
hydroelectrolyt
balanc
two
layer
skin
epidermi
dermi
first
one
avascular
compos
stratifi
keratin
squamou
epithelium
four
layer
bottom
basal
spinosum
granulosum
corneum
thick
skin
palm
sole
fifth
layer
superfici
corneum
call
lucidum
dermi
consist
two
layer
reticular
superfici
papillari
connect
tissu
elastin
collagen
fibr
compon
blood
lymphat
vessel
network
nerv
touch
receptor
meissner
corpuscl
adipocyt
phagocyt
hair
follicl
sweat
gland
topic
skin
drug
deliveri
local
effect
requir
less
drug
target
outcom
transderm
therapi
result
fewer
side
effect
need
regular
treatment
system
distribut
drug
method
treatment
common
blockag
stratum
corneum
pass
barrier
differ
approach
develop
base
mostli
disrupt
structur
chemic
substanc
like
surfact
alcohol
ester
amin
terpen
alkan
phospholipid
mechan
use
ultrasound
micro
needl
magnetophoresi
iontophoresi
electropor
laser
excess
use
though
damag
skin
analys
literatur
data
suggest
differ
process
mechan
govern
penetr
smalllarg
molecul
skin
barrier
accord
schneider
et
al
review
two
gener
pathway
skin
absorpt
skin
appendag
stratum
corneum
underli
layer
lipophil
statum
corneum
medium
determin
first
mechan
skin
penetr
name
absorpt
lipophil
compound
three
transport
rout
substanc
across
stratum
corneum
classifi
transcellular
intercellular
transappendag
pathway
defin
liang
et
al
exampl
avail
conclus
full
understand
penetr
absorpt
process
still
evalu
due
challeng
associ
deliv
complex
burden
skin
barri
specifi
section
current
antivir
therapi
hsv
infect
includ
topic
formul
acv
unabl
permeat
stratum
corneum
target
viru
site
basal
epidermi
due
polar
solubl
lead
poor
clinic
efficaci
due
delay
antivir
activ
subinhibitori
concentr
nanotechnolog
strategi
seem
facilit
admiss
fee
due
ration
design
innov
function
synthes
nanoplatform
present
figur
one
problem
dermal
drug
pass
relat
inflamm
skin
patholog
barrier
chang
drug
resid
much
less
target
site
fast
penetr
thermorespons
drug
deliveri
nanogel
use
purpos
encourag
result
overcom
abovement
problem
ph
sensit
nanogel
also
utilis
control
medicin
releas
epidermi
due
polar
solubl
lead
poor
clinic
efficaci
due
delay
antivir
activ
subinhibitori
concentr
nanotechnolog
strategi
seem
facilit
admiss
fee
due
ration
design
innov
function
synthes
nanoplatform
present
figur
one
problem
dermal
drug
pass
relat
inflamm
skin
patholog
barrier
chang
drug
resid
much
less
target
site
fast
penetr
thermorespons
drug
deliveri
nanogel
use
purpos
encourag
result
overcom
abovement
problem
ph
sensit
nanogel
also
utilis
control
medicin
releas
thermorespons
nanogel
control
irradi
infrar
lamp
anoth
way
skin
penetr
hair
follicl
stratum
corneum
less
intact
lower
infundibulum
nanoparticl
np
passag
depend
size
composit
cell
membran
separ
content
cell
exterior
surround
besid
standard
protect
around
cell
cell
membran
control
substanc
go
composit
base
bilay
phospholipid
intern
hydrophob
tail
extern
hydrophil
head
differ
protein
cholesterol
membran
permeabl
select
permit
materi
pass
lipid
layer
activ
protein
pump
vesicl
passiv
diffus
process
transport
water
pass
membran
process
call
osmosi
occur
imbal
solut
appear
outsid
insid
cell
case
hydrophob
small
molecul
pass
diffus
nanoscal
drug
deliveri
system
depend
upon
activ
mechan
endocytosi
process
cell
unit
take
ion
solid
particl
molecul
studi
prove
posit
charg
nanogel
bind
membran
cell
neg
charg
electrostat
intercommun
receptormedi
endocytosi
provid
mechan
select
attract
cell
group
target
addit
hydrophob
nanoplatform
grow
adhes
membran
amount
drug
enter
cell
thermorespons
nanogel
control
irradi
infrar
lamp
anoth
way
skin
penetr
hair
follicl
stratum
corneum
less
intact
lower
infundibulum
nanoparticl
np
passag
depend
size
composit
cell
membran
separ
content
cell
exterior
surround
besid
standard
protect
around
cell
cell
membran
control
substanc
go
composit
base
bilay
phospholipid
intern
hydrophob
tail
extern
hydrophil
head
differ
protein
cholesterol
membran
permeabl
select
permit
materi
pass
lipid
layer
activ
protein
pump
vesicl
passiv
diffus
process
transport
water
pass
membran
process
call
osmosi
occur
imbal
solut
appear
outsid
insid
cell
case
hydrophob
small
molecul
pass
diffus
nanoscal
drug
deliveri
system
depend
upon
activ
mechan
endocytosi
process
cell
unit
take
ion
solid
particl
molecul
studi
prove
posit
charg
nanogel
bind
membran
cell
neg
charg
electrostat
intercommun
receptormedi
endocytosi
provid
mechan
select
attract
cell
group
target
addit
hydrophob
nanoplatform
grow
adhes
membran
amount
drug
enter
cell
bbb
highli
select
semiperm
structur
compos
five
part
basement
membran
astrocyt
immun
cell
pericyt
endotheli
cell
layer
capillari
area
basement
membran
neuron
call
virchowrobin
space
region
interstiti
fluid
resid
microglia
compon
call
neurovascular
unit
kinet
unit
crucial
role
bbb
state
ill
capillari
bbb
compos
layer
squamou
epitheli
cell
fold
form
circular
vessel
cell
link
strong
connect
block
entranc
exit
materi
central
nervou
system
protein
transport
facilit
select
flow
molecul
vessel
lumen
essenti
biomolecul
higher
concentr
like
glucos
time
elimin
toxin
bbb
physic
metabol
obstacl
physiolog
import
activ
survey
bloodbrain
traffic
control
restrict
paracellular
diffus
endotheli
cell
microvessel
efflux
pump
activ
quickli
expel
back
capillari
lumen
wide
varieti
xenobiot
bbb
integr
function
critic
influenc
refer
extend
neurovascular
unit
incorpor
microvascular
endotheli
cell
adjac
pericyt
astrocyt
neuron
also
neighbour
smooth
muscl
cell
microglia
brain
blood
cell
capillari
lumen
polymorphonuclear
cell
lymphocyt
monocyt
transport
bbb
level
assur
numer
transport
mechan
provid
brain
necessari
nutrient
also
protect
toxic
xenobiot
main
transport
mechan
repres
free
diffus
small
lipophil
substanc
activ
transport
carrier
mediat
receptor
mediat
activ
efflux
transport
activ
efflux
transport
assur
two
major
type
transport
extrud
metabol
wast
xenobiot
larg
number
drug
brain
back
blood
first
superfamili
bbb
efflux
transport
solut
carrier
protein
slc
superfamili
repres
level
bbb
slco
efflux
transport
second
atpbind
cassett
abc
efflux
transport
famili
repres
permeabl
glycoprotein
pgp
breast
cancer
resist
protein
bcrp
multidrug
resist
associ
protein
mrp
base
localis
abc
efflux
transport
prevent
lipophil
amphiphil
environment
toxic
compound
drug
includ
antiinflammatori
immunosuppress
antiinfecti
antineoplast
drug
antiepilept
antidepress
psychotrop
agent
drug
conjug
energydepend
unidirect
direct
transport
mechan
enter
specif
substrat
bbb
efflux
machineri
excel
job
recogn
xenobiot
poor
job
distinguish
toxic
therapeut
drug
creat
import
obstacl
treatment
brain
cancer
epilepsi
neuro
aid
penetr
bbb
drug
deliveri
although
challeng
captiv
interest
numer
research
antivir
therapi
sinc
mechan
exampl
penetr
cn
remain
unclear
like
rout
includ
retrograd
transport
via
olfactori
trigemin
nerv
fibr
occasion
lead
herp
simplex
enceph
hse
caus
anoth
studi
viru
involv
enceph
bbb
disrupt
hiv
known
caus
sever
neurolog
disord
lead
hivrel
enceph
sinc
bbb
imperm
antiretrovir
drug
possibl
mechan
respons
bbb
disrupt
enceph
consid
trojan
hors
mechan
hiv
infect
specif
tlymphocyt
circul
monocyt
enter
cn
bbb
gap
follow
inflammatori
reaction
last
year
nanotechnolog
intens
explor
sever
experiment
attempt
carri
order
enhanc
bbb
permeabl
toward
antiretrovir
drug
briefli
describ
base
nanobas
formul
composit
sinc
well
known
size
surfac
function
influenc
transport
properti
within
tissu
polymer
polybutylcyanoacryl
pbca
nanoparticl
two
incorpor
antiretrovir
drug
azt
lamivudin
show
fold
increas
bbb
permeat
three
possibl
mechan
present
author
prolong
interact
interv
drugload
nanoparticl
brainmicrovascular
endotheli
cell
elev
concentr
gradient
blood
brain
polysorb
cover
peripheri
nanoparticl
abl
absorb
degrad
nanoparticl
improv
drug
absorpt
spheric
transferrin
coatedpegyl
albumin
nanoparticl
encapsul
azt
prepar
ultraemulsif
method
use
chemic
crosslink
glutaraldehyd
gain
access
across
bbb
transferrin
receptor
mediat
endocytosi
membran
transferrinconjug
quantum
rod
nanoparticl
conjug
saquinavir
cross
vitro
bbb
model
exploit
receptormedi
transport
magnet
liposom
nanoformul
azidothymidin
triphosph
activ
form
azidothymidin
migrat
across
bbb
vitro
either
directli
monocytemedi
transport
influenc
extern
magnet
field
novel
nanodrug
consist
iron
oxid
nanoparticl
coat
pma
amphiphil
polym
function
antiretrovir
peptid
enfuvirtid
cross
bbb
passiv
diffus
probabl
mediat
absorpt
amphiphil
coat
cell
membran
briefli
present
preliminari
result
encourag
certainli
futur
investig
mechan
bbb
disrupt
need
along
novel
innov
safe
efficaci
therapeut
approach
conclud
current
antivir
therapi
yet
achiev
ideal
shape
effici
also
complex
biolog
barrier
major
obstacl
critic
say
nanotechnolog
could
identifi
solut
search
engin
queri
nanotechnolog
gener
item
special
platform
scienc
direct
exampl
repres
potenti
challeng
differ
field
biosensor
industryrel
applic
nanomedicin
biomateri
search
keyword
nanotechnolog
antivir
therapi
engin
return
result
start
given
fact
nanotechnolog
defin
applic
materi
nanomet
scale
accord
literatur
data
result
namomateri
design
differ
shape
morpholog
display
numer
advantag
use
antivir
therapi
name
nanometr
size
permit
drug
deliveri
imperm
barrier
larg
surfac
area
volum
ratio
larg
drug
payload
incorpor
improv
efficaci
surfac
modif
andor
backbon
function
versatil
facilit
cellular
membran
passag
enhanc
stabil
bioavail
virucid
activ
seri
virus
hiv
hsv
hbv
etc
due
biomimet
properti
increas
specif
improv
antivir
deliveri
control
drug
releas
target
engin
moieti
decreas
emerg
drug
resist
person
therapi
possibl
protect
drug
low
advers
drug
side
effect
mainli
due
composit
mechan
nanomaterialmedi
drug
deliveri
determin
chemistri
architectur
specif
properti
nanosystem
present
schemat
represent
figur
design
new
drug
deliveri
system
antivir
therapi
focus
manipul
featur
relev
viral
diseas
high
drug
dose
compulsori
impli
high
cost
patient
depend
administr
protocol
lembo
caval
present
current
statu
nanoparticul
deliveri
system
antivir
therapi
area
highlight
perspect
challeng
must
tackl
nanotechnolog
translat
clinic
use
safe
effect
antivir
formul
therefor
nanoparticul
antivir
system
synthesis
consist
mainli
micel
polymer
np
solid
lipid
np
sln
nanostructur
lipid
carrier
nlc
liposom
nanocapsul
vesicl
dendrim
nanogel
cyclodextrinbas
system
emuls
tackl
nanotechnolog
translat
clinic
use
safe
effect
antivir
formul
therefor
nanoparticul
antivir
system
synthesis
consist
mainli
micel
polymer
np
solid
lipid
np
sln
nanostructur
lipid
carrier
nlc
liposom
nanocapsul
vesicl
dendrim
nanogel
cyclodextrinbas
system
emuls
liu
chen
summar
review
paper
interest
perspect
nanotechnolog
use
hivaid
vaccin
develop
overview
underlin
potenti
variou
nanomateri
nanoarchitectur
use
hiv
vaccin
carrier
adjuv
due
proven
capabl
improv
deliveri
permeabl
stabil
solubl
pharmacokinet
tradit
hiv
vaccin
approach
author
exhibit
also
desir
featur
nanocarri
adjuv
high
benefitscost
ratio
milovanov
et
al
outlin
besid
viru
replic
cycl
mechan
action
antivir
agent
overview
particul
carrier
drug
deliveri
review
summar
sever
class
mostli
consid
carrier
name
liposom
micel
microspher
dendrim
np
synthes
altern
support
antivir
therapi
tabl
highlight
part
summari
describ
base
viru
classif
section
cao
woodrow
review
nanotechnolog
solut
use
erad
hiv
reservoir
also
gene
deliveri
immunotherapi
nanocarri
use
cancer
potenti
hiv
treatment
section
nanocarri
erad
hiv
reservoir
author
focus
mainli
nanocarri
incorpor
combin
therapeut
develop
order
boost
drug
effect
minim
toxic
sever
exampl
present
tabl
describ
section
liu
chen
summar
review
paper
interest
perspect
nanotechnolog
use
hivaid
vaccin
develop
overview
underlin
potenti
variou
nanomateri
nanoarchitectur
use
hiv
vaccin
carrier
adjuv
due
proven
capabl
improv
deliveri
permeabl
stabil
solubl
pharmacokinet
tradit
hiv
vaccin
approach
author
exhibit
also
desir
featur
nanocarri
adjuv
high
benefitscost
ratio
milovanov
et
al
outlin
besid
viru
replic
cycl
mechan
action
antivir
agent
overview
particul
carrier
drug
deliveri
review
summar
sever
class
mostli
consid
carrier
name
liposom
micel
microspher
dendrim
np
synthes
altern
support
antivir
therapi
tabl
highlight
part
summari
describ
base
viru
classif
section
cao
woodrow
review
nanotechnolog
solut
use
erad
hiv
reservoir
also
gene
deliveri
immunotherapi
nanocarri
use
cancer
potenti
hiv
treatment
section
nanocarri
erad
hiv
reservoir
author
focus
mainli
nanocarri
incorpor
combin
therapeut
develop
order
boost
drug
effect
minim
toxic
sever
exampl
present
tabl
describ
section
recent
arcalafuent
et
al
overview
nanotechnologybas
system
reliabl
altern
diagnost
tool
hcv
infecti
diseas
even
review
cover
screen
import
mention
new
diagnost
method
requir
order
overcom
current
drawback
hcv
underdiagnos
infect
highlight
abovement
review
nanotechnologybas
tool
describ
review
seem
fulfil
necessari
featur
hcv
elimin
aim
develop
new
person
diagnost
tool
farzin
et
al
summar
current
strategi
underdevelop
tool
earli
diagnosi
hiv
review
combin
use
nanomateri
carbon
nanostructur
nanoclust
quantum
dot
metal
metal
oxid
np
advanc
structur
hiv
detect
possibl
biosens
strategi
target
offer
innov
outlook
develop
intellig
sensit
specif
nanoobject
situ
realtim
detect
hiv
section
author
point
suitabl
nanomateri
recent
data
antivir
therapi
highlight
enhanc
featur
pursu
overcom
identifi
issu
relat
donalisio
et
al
report
prepar
modifi
nanoemuls
method
chitosan
nanospher
ns
load
acv
topic
formul
herp
viru
strain
main
compon
chitosan
natur
polycation
polysaccharid
select
materi
acv
releas
due
distinct
properti
hydrophil
charact
situ
gell
mucoadhes
permeat
enhanc
addit
low
cytotox
biocompat
bioresorb
featur
obtain
gel
formul
base
acvload
ns
prove
enhanc
abil
penetr
porcin
skin
h
greater
commerci
cream
product
ic
valu
also
determin
vero
cell
cultur
infect
abovement
strain
display
signific
reduc
valu
respect
use
ns
formul
compar
free
acyclovir
nanotechnolog
approach
attest
higher
efficaci
describ
formul
promis
expect
preclin
clinic
experi
yadav
et
al
explor
potenti
highli
porou
activ
carbon
hpac
particl
model
restrict
enter
target
cell
consid
materi
due
charcoal
surfaceact
could
provid
antivir
effect
virion
sequestr
approach
furthermor
acv
molecul
adsorb
encapsul
insid
hpac
pore
reveal
sustain
drug
releas
act
synergist
manner
obtain
enhanc
therapeut
effect
hpac
compound
prove
reduct
entri
concentr
low
mgml
ic
valu
hpac
correspond
infect
prophylact
administr
found
mgml
respect
significantli
lower
clinic
accept
valu
half
maxim
toxic
concentr
hpac
follow
promis
outcom
vitro
test
determin
antivir
efficaci
vivo
studi
use
murin
model
ocular
genit
infect
perform
result
acv
load
hpac
act
captur
viru
releas
encapsul
drug
hinder
inflamm
immun
cell
infiltr
target
tissu
strong
antivir
activ
product
assign
charg
surfac
pore
may
interact
cell
surfac
stimul
activ
exchang
ion
na
k
ca
cl
oh
sustain
slow
releas
acv
acquir
moreov
particl
exhibit
prophylact
therapeut
effect
cell
unlik
free
drug
demonstr
prophylact
antivir
respons
gold
silver
np
use
seawe
sargassum
wightii
antiherpet
activ
biogen
gold
au
silver
ag
np
prepar
use
seawe
sargassum
wightii
sw
investig
antivir
activ
strain
np
synthesi
resid
ecofriendli
method
previous
describ
literatur
replac
use
differ
reduc
agent
obtain
np
swau
swag
evalu
concern
cytotox
antivir
effect
use
mtt
cpe
cytopath
effect
assay
vero
cell
result
show
cell
viabil
rang
concentr
rang
per
sampl
swau
concentr
per
sampl
swag
antivir
assay
shown
decreas
cpe
vero
cell
treat
swau
wherea
swag
exhibit
similar
reduct
cpe
concentr
per
sampl
higher
concentr
swag
accept
due
increas
cytotox
effect
author
claim
obtain
result
agreement
publish
research
infer
function
metal
np
act
antivir
agent
block
viru
attach
cell
access
depend
particl
size
cagno
et
al
conduct
research
studi
concern
broadspectrum
antivir
product
usual
mimic
heparan
sulfat
proteoglycan
hspg
wellpreserv
target
viral
attach
ligand
val
antivir
effect
reli
bind
mechan
nanoparticl
viru
surfac
thu
prevent
viruscel
attach
case
revers
bond
report
increas
dilut
viral
inhibit
lost
caus
compound
consid
antivir
drug
aforement
author
design
antivir
nanoparticl
virucid
effect
base
long
flexibl
linker
simul
hspg
lead
irrevers
viral
deform
synthes
compound
notabl
virucid
effect
found
aunp
coat
mixtur
decanesulfon
acid
mu
ot
mu
allow
multival
bind
consequ
structur
compris
long
hydrophob
chain
sulfon
acid
termin
enhanc
activ
mu
otnp
assign
new
construct
use
mu
linker
caus
local
distort
global
viru
deform
lead
irrevers
loss
infect
mu
otnp
exhibit
effici
virucid
effect
human
papilloma
viru
respiratori
syncyti
viru
rsv
dengu
lenti
viru
vivo
test
balbc
mice
infect
rsv
reveal
efficaci
mu
otnp
treatment
prevent
pulmonari
dissemin
infect
result
agreement
previou
publish
data
assess
relationship
surfac
structur
nanoobject
abil
cross
cell
membran
vivo
vitro
test
cell
cultur
proven
lack
toxic
mu
otnp
coumestrol
isoflavonoidlik
compound
abil
inhibit
replic
acyclovir
sensit
resist
strain
also
strain
argenta
et
al
design
formul
effort
obtain
topic
product
coumestrol
deliveri
level
mucosa
approach
bioactiv
compound
entrap
fluid
rigid
phospholipid
nanoemuls
dioleylphosphocholin
dopc
distearoylphosphocholin
dspc
respect
dispers
hydroxyethylcellulos
gel
effect
propos
antivir
agent
test
regard
permeat
retent
abil
intact
damag
porcin
esophag
mucosa
antiherp
activ
cell
cultur
assay
use
vero
gmk
cell
line
greatest
perform
coumestrolload
nanoemuls
necoudopc
product
thicken
hydroxyethylcellulos
hnecoudopc
compar
base
dspc
reli
larg
physicochem
properti
nanoemuls
posit
charg
nanoemuls
show
highest
valu
may
interact
neg
charg
surfac
mucosa
membran
benefici
consequ
relat
transmucos
deliveri
coumestrol
length
phospholipid
alkyl
chain
number
unsatur
lipophilichydrophil
balanc
activ
principl
also
contribut
global
effect
fluidstat
hydrocarbon
chain
induc
dopc
explain
interact
oilwat
interfac
mucosa
increas
coumestrol
permeat
retent
low
ic
valu
prove
enhanc
antivir
activ
coumestrol
formul
use
nanoemuls
base
dopc
could
consid
advanc
studi
order
introduc
therapi
huge
socioeconom
impact
hiv
mention
section
determin
continu
increas
trend
studi
relat
find
almost
perfect
treatment
sinc
seven
class
antiretrovir
drug
defin
fda
contain
larg
number
activ
principl
plenti
studi
regard
incorpor
differ
type
nanosystem
found
literatur
sever
exampl
present
rti
class
nrti
nnrti
includ
drug
often
use
hiv
treatment
plan
recent
grand
et
al
publish
complex
review
rti
nanosystem
control
drug
deliveri
review
complement
part
data
present
articl
emphas
penetr
biolog
barrier
vitro
vivo
nanosystem
contain
rti
azt
high
bioavail
drug
seriou
side
effect
common
bone
marrow
suppress
toxic
organ
neutropenia
anaemia
specif
target
drug
deliveri
use
differ
nanosystem
promis
solut
atz
incorpor
hybrid
np
base
algin
stearic
acidpoli
ethylen
glycol
glioma
neuro
brain
hela
cell
use
studi
cellular
uptak
cytotox
np
vitro
result
prove
nanosystem
nontox
signific
brain
cellular
uptak
suggest
use
complex
intern
brain
cell
studi
anoth
studi
soloil
chemistri
use
prepar
small
np
lactoferrin
load
azt
nm
size
stabl
biolog
simul
fluid
gastric
intestin
antivir
activ
np
analys
use
cell
infect
viru
result
suggest
encapsul
azt
lactoferrin
influenc
drug
activ
np
load
azt
drug
alon
oral
administr
wistar
rat
gender
perform
assay
bone
marrow
micronucleu
histopatholog
biochem
analysi
show
azt
load
np
effici
less
toxic
compar
solubl
form
lamivudinelam
watersolubl
drug
two
main
drawback
halflif
h
defici
bioavail
especi
paediatr
patient
lam
includ
np
base
poli
pcl
poli
lacticcoglycol
acidplga
chitosan
sodium
algin
eudragit
physicochem
character
obtain
np
shown
adequ
size
np
good
stabil
vitro
drug
releas
test
indic
np
support
drug
deliveri
h
indic
less
frequent
administr
sneba
et
al
report
complex
studi
lampolymer
noncytotox
np
includ
film
drug
deliveri
buccal
mucosa
barrier
four
mucoadhes
polym
polyvinyl
alcoholpva
polyvinyl
pyrrolidonepvp
sodium
carboxymethylcellulosescm
hydroxypropyl
methylcellulosehpmc
use
prepar
film
moreov
ozturk
et
al
obtain
plga
np
load
lam
prove
physicochem
stabl
slowli
releas
drug
great
properti
attribut
ester
endgroup
plga
np
intend
oral
administr
author
evalu
gastrointestin
stabil
np
vitro
use
differ
fluid
biolog
interest
ph
rang
phosphat
buffer
solut
intestin
fluid
phosphat
buffer
solut
physiolog
serum
distil
water
test
develop
c
h
result
indic
plga
np
promis
intestin
target
drug
deliveri
system
lma
stabl
test
media
clinic
practic
lam
frequent
administr
togeth
azt
therefor
combin
drug
studi
target
deliveri
use
differ
type
np
sankar
et
al
use
plga
methylmethacrylatesulfopropylmethacrylatemmaspm
poli
lactic
acidpla
poli
methyl
methacrylatepmma
prepar
differ
type
np
emuls
polymer
drug
deliveri
nanosystem
atz
lma
vivo
acut
toxic
studi
mice
result
prove
fact
drug
dose
load
np
toxic
atzlam
plga
np
seem
promis
nanosystem
efavirenzefv
one
use
nnrti
clinic
practic
poorli
watersolubl
drug
incorpor
differ
drug
deliveri
nanosystem
solut
drawback
patel
et
al
obtain
nanosuspensionsn
base
povidon
polymerpolyvinylpyrrolidon
pvp
poloxam
steric
stabil
anion
electrostat
stabil
sodium
lauryl
sulphat
steric
stabilizersl
compar
drug
alon
import
improv
satur
solubl
notic
ns
efv
incornepor
efv
ns
increas
absorpt
drug
rat
intestin
situ
import
oral
bioavail
studi
albino
rabbit
lactoferin
use
prepar
np
load
atz
describ
use
also
encapsul
efv
base
prepar
techniqu
soloil
chemistri
compar
free
efv
encapsul
drug
np
show
reduc
toxic
peripher
blood
mononuclear
cell
jurkat
cell
cell
increas
activ
improv
oral
bioavail
pharmacokinet
profil
studi
rat
atv
low
brain
permeabl
antiretrovir
drug
resist
two
import
disadvantag
atv
pi
drug
encapsul
sln
studi
nanosystem
brain
deliveri
use
bloodbrain
barrier
vitro
model
human
brain
microvessel
endotheli
cell
line
averag
atv
import
increas
regard
cellular
uptak
deliv
averag
nanosystem
around
nm
sqv
anoth
antihiv
pi
incorpor
poli
ethylen
oxid
modifi
poli
peopcl
np
solvent
displac
process
human
monocyt
macrophag
momac
cell
use
vitro
cellular
uptak
assay
drug
success
releas
intracellular
meaning
uptak
sqvpeopcl
notic
nfv
use
treatment
pi
promis
drug
use
also
grave
medic
disord
like
cancer
studi
show
abil
differ
type
np
load
nfv
activ
latent
hiv
restrict
viral
spread
vitro
kovochich
et
al
show
lipid
npslnp
incorpor
protein
kinas
c
activ
lnpbri
load
nfv
lnpbrynfv
prove
mention
abil
jlat
full
length
cell
tang
et
al
prepar
np
base
poli
lacticcoglycol
acid
polyethylen
glycol
diblock
copolym
antibodi
conjug
suberoylanilid
hydroxam
acid
saha
nfv
test
vitro
properti
cell
complex
studi
perform
venkatesh
et
al
plga
np
load
nfv
significantli
enhanc
oral
bioavail
drug
studi
vivo
new
zealand
rabbit
reduc
frequenc
dose
need
case
literatur
data
report
also
sever
studi
combin
pi
drug
incorpor
nanosystem
preclin
evalu
duan
et
al
includ
separ
atv
drv
lnp
atvlnp
prove
form
stabl
druglipid
concentr
base
result
author
develop
lnp
contain
atv
rtv
also
lnp
contain
atv
rtv
tenofovir
tfvan
hiv
nrti
last
one
prepar
larg
volum
preliminari
primat
pharmacokinet
studi
lnp
subcutan
administr
three
drug
detect
plasma
seven
day
enf
fusion
inhibitor
incap
cross
cerebrospin
fluid
fiandra
et
al
prove
includ
nanosystem
compos
magnet
nanoparticl
mnp
synthes
solvotherm
decomposit
organ
solvent
follow
fluoresc
label
pma
coat
could
solv
enf
drawback
vitro
model
cocoltur
rbmvec
astrocyt
vivo
model
balbc
mice
studi
prove
nanoconjug
enf
could
penetr
bbb
mcv
entri
inhibitor
act
coreceptor
antagonist
also
includ
nanosystem
order
increas
oral
bioavail
solid
drug
nanoparticlessdn
contain
wt
mvc
polymersurfact
excipi
prepar
use
emulsiontempl
freez
dri
techniqu
monolay
use
human
gut
vitro
model
order
studi
absorpt
behaviour
mvc
sdn
vivo
oral
pharmacokinet
mvc
solid
drug
nanoparticl
sdn
analys
rat
model
studi
indic
advanc
permeabl
mcv
np
base
pva
sodium
aot
excipi
correl
normal
drug
bowman
et
al
prove
small
organ
monoval
molecul
conjug
aunp
act
fusion
inhibitor
vitro
vijayakumar
et
al
prove
aunp
alon
act
entri
inhibitor
moreov
integras
inhibitor
ral
function
thiol
group
order
link
aunp
vitro
cellular
uptak
test
macrophag
human
brain
microendotheli
cell
primari
peripher
blood
mononuclear
cell
result
suggest
ralpmbaaunp
penetr
cell
also
exhibit
antivir
activ
vivo
studi
perform
inject
ralpmbaaunp
femal
adult
balb
mice
tail
prove
studi
np
could
cross
bbb
nanomedicin
repres
fastrevolution
field
face
rapidli
constantli
progress
assess
numer
nanodrug
enter
clinic
practic
also
even
investig
clinic
trial
tabl
present
approv
antivir
nanomedicin
half
vaccin
accord
singh
et
al
review
also
avail
inform
respect
websit
still
sever
nanomedicin
evalu
name
fluquit
stp
sirnaom
inc
current
preclin
evalu
polymerbas
nanotherapeut
incorpor
sirna
target
avian
flu
swine
flu
influenza
newli
emerg
cervisil
nanobas
drug
candid
incorpor
sirna
treatment
dermavir
genet
immun
synthet
pathogenlik
nanomedicin
incorpor
singl
plasmid
dna
express
hiv
antigen
assembl
hivlik
particl
dermavir
vaccin
complet
phase
iii
random
placebocontrol
dosefind
doubleblind
multicent
studi
assess
safeti
toler
immun
respons
adult
current
receiv
antihiv
treatment
number
doravirin
merck
novel
next
gener
nnrti
describ
solid
drug
nanoparticl
formul
test
hiv
current
doravirin
complet
pharmacokinet
trial
bioavail
four
nano
formul
healthi
adult
number
lipid
nanoparticl
tkmhbv
contain
three
rnai
therapeut
hbv
genom
target
arbutu
biopharma
compani
complet
phase
singl
blind
random
placebo
control
studi
evalu
safeti
antivir
activ
pharmacokinet
pk
follow
multipl
dose
intraven
number
discuss
nanotechnolog
start
critic
player
antivir
therapi
mention
ross
et
al
nanotechnolog
free
current
therapi
payload
term
deliveri
across
biolog
complex
barrier
could
resolv
low
bioavail
drawback
alreadi
state
section
nanomateri
impart
mani
physic
chemic
biolog
advantag
small
particl
size
order
facilit
drug
deliveri
biolog
barrier
larg
surfac
area
volum
ratio
ensur
larg
drug
payload
tunabl
surfac
charg
facilit
cellular
entri
across
neg
charg
cellular
membran
biomimet
properti
result
intrins
antivir
asset
abil
anchor
target
moieti
increas
specif
desir
cell
type
tissu
compart
improv
solubl
pharmacokinet
andor
pharmacodynam
properti
translat
longer
time
allow
greater
accumul
control
sustain
releas
enhanc
effici
gain
either
drug
molecul
entrap
protect
physiolog
hostil
media
use
surfac
conjug
target
drug
specif
tissu
reduc
toxic
multifunction
combin
sever
benefici
featur
stabl
construct
design
simultan
stimul
replic
latent
viru
deliv
antivir
activ
cell
sever
limit
also
acknowledg
degrad
exampl
nanoparticl
degrad
gut
follow
oral
administr
fail
penetr
mucu
barrier
thu
minim
absorb
undesir
interact
biolog
molecul
lead
opson
uptak
macrophag
reduc
plasma
halflif
nonspecif
absorpt
may
induc
apoptosi
disrupt
cell
membran
advers
immunolog
respons
larg
dimens
renal
clearanc
therefor
degrad
within
bodi
accumul
lead
toxic
scale
issu
high
cost
perspect
ideal
nanocarri
effici
antivir
deliveri
must
take
consider
sever
key
factor
name
clinic
outcom
sinc
patient
need
safe
effect
target
avail
afford
therapi
inspir
clinic
perspect
futur
antivir
candid
improv
efficaci
fusedencapsul
drug
reduc
intak
frequenc
time
restrict
advers
side
effect
reduc
therapi
cost
design
consider
nanoplatform
allow
target
deliveri
drug
sustain
releas
manner
improv
efficaci
safeti
patient
conveni
therefor
chemist
point
view
hybrid
nanosystem
gather
necessari
featur
term
composit
shape
size
overcom
limit
individu
system
offer
greater
advantag
start
composit
chosen
materi
biodegrad
biocompat
nontox
exampl
polym
attract
sinc
offer
possibl
chemic
modif
surfac
backbon
addit
advantag
second
compon
hybrid
architectur
shape
potenti
liposom
offer
besid
advanc
barrier
penetr
higher
encapsul
effici
intend
drug
combin
polymer
piec
abl
modul
releas
kinet
stabil
prolong
drug
releas
think
shape
mind
target
capabl
impact
alreadi
know
shape
link
size
surfac
charg
densiti
therefor
complex
puzzl
must
solv
surfac
charg
densiti
care
chosen
nanoplatform
design
surfac
modif
possibl
ideal
candid
perspect
peg
due
versatil
exhibit
variou
charg
shape
size
also
enhanc
toler
reduc
clearanc
lengthen
circul
time
size
influenc
biodistribut
uptak
rate
therefor
nomine
submicron
size
rang
recommend
nm
take
consider
perform
indic
nanomedicin
claim
develop
person
nanomedicin
possibl
via
synergist
approach
sinc
develop
best
viral
carrier
involv
multidisciplinari
team
virologist
directli
implic
develop
offer
special
support
follow
matter
identif
differenti
express
moieti
viru
cell
target
deliveri
elucid
type
desir
target
respons
host
cell
nanodeliveri
platform
therefor
multidisciplinari
researchori
effort
relat
also
system
biolog
explor
machin
learn
process
optim
pharmacolog
order
introduc
best
appropri
combin
therapeut
agent
interdisciplinari
team
virologist
biochemist
develop
lowcost
cellfriendli
nanogel
effici
prevent
viral
infect
address
challeng
flexibl
nontox
broadspectrum
nanogel
base
dendrit
polyglycerol
sulfat
mimic
cellular
surfac
receptor
sever
viral
famili
bind
design
nanogel
multival
interact
viral
glycoprotein
shield
viru
surfac
effici
block
infect
sinc
act
robust
inhibitor
virus
think
translat
clinic
practic
nanobas
futur
antivir
therapi
must
follow
specif
flowchart
start
optim
scaleup
practic
accord
good
manufactur
practic
elabor
suitabl
regulatori
guidelin
finish
develop
costeffect
high
qualiti
formul
avail
worldwid
taken
consider
enhanc
featur
road
clinic
practic
still
mani
address
issu
order
provid
effect
safe
antivir
nanoformul
patient
treat
improv
treatment
success
rate
viral
diseas
fundament
respons
establish
potenti
boost
progress
nanotechnolog
antivir
therapi
develop
gener
great
expect
new
therapeut
innov
strategi
attack
erad
viral
disord
present
studi
explor
numer
divers
nanoplatform
includ
nanoparticl
liposom
micel
differ
composit
size
singl
combin
entrap
drug
may
serv
potenti
antivir
drug
deliveri
transport
nanobas
system
exhibit
versatil
featur
improv
identifi
current
therapi
drawback
howev
clinic
use
nanobas
antivir
formul
date
base
knowledg
turn
approv
clinic
trial
nanoformul
mainli
vaccin
despit
year
constant
effort
expect
upcom
year
part
success
preclin
stori
scaledup
translat
appli
better
outcom
conveni
access
patient
